Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | F7 | P08709 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612580 | 0.92 | SMPD1 (0.48) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3543357 | 0.90 | MAPT (0.39) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL13439291 | 0.90 | SMPD1 (0.47) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL13439288 | 0.86 | KMT2A (0.49) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL7444186 | 0.85 | ALDH1A1 (0.46) | HDAC8ALDH1A1CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL7432355 | 0.84 | MAOB (0.50) | ALDH1A1SMN1; SMN2MEN1KMT2APDE4A | |
| SCHEMBL19586903 | 0.83 | KMT2A (0.52) | SMPD1SMN1; SMN2MEN1KMT2ACTSV | |
| SCHEMBL2990764 | 0.80 | SMPD1 (0.55) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL4125403 | 0.80 | ALDH1A1 (0.60) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL5429879 | 0.80 | SMPD1 (0.47) | SMPD1HDAC1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696198-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| EP-1435944-B1 | 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | MEMORY PHARM CORP (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090176799-A1 | PHOSPHODIESTERASE 4 INHIBITORS | RUIPING LIU | 2009-07-09 | — | — | US | disclosed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7235579-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1613590-A2 | 4-(3,4-DISUBSTITUTED PHENYL)-PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050272803-A1 | Phosphodiesterase 4 inhibitors | RUIPING LIU | 2005-12-08 | — | — | US | disclosed |
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2004094375-A2 | 4 - (3,4 - DISUBSTITUTED PHENYL) - PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1435944-A1 | 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | Memory Pharmaceutical Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030139406-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003032981-A1 | 4-(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | MEMORY PHARMACEUTICALS CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139406-A1 | Phosphodiesterase 4 inhibitors | PDE12, PDE4A, PDE5A | SMPD1 49/4885HDAC1 123/4885HDAC8 522/4885 |
| US-20090176799-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE12, PDE3B | SMPD1 70/4885HDAC1 128/4885HDAC8 475/4885 |
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | SMPD1 70/4885HDAC1 128/4885HDAC8 475/4885 |
| US-20050272803-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | SMPD1 70/4885HDAC1 128/4885HDAC8 475/4885 |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | PDE4A, PDE4B, PDE12 | SMPD1 116/4885HDAC1 1191/4885HDAC8 1458/4885 |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE5A | SMPD1 33/4885HDAC1 200/4885HDAC8 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.